No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan

CPT-11 (irinotecan) is a DNA-topoisomerase I inhibitor with preclinical activity against neuroblastoma (NB) xenografts. The aim was to establish in vivo an NB xenograft resistant to CPT-11 in order to study the resistance mechanisms acquired in a therapeutic setting. IGR-NB8 is an immature NB xenogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvet, L, Santos, A, Valent, A, Terrier-Lacombe, M-J, Opolon, P, Merlin, J-L, Aubert, G, Morizet, J, Schellens, J H M, Bénard, J, Vassal, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747712/
https://www.ncbi.nlm.nih.gov/pubmed/15292932
http://dx.doi.org/10.1038/sj.bjc.6602079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747712/
https://www.ncbi.nlm.nih.gov/pubmed/15292932
http://dx.doi.org/10.1038/sj.bjc.6602079

Ejemplares similares